You are here: Home > Our Business > Pipeline


DTcP (Infant)


DTcP vaccine is for infants (below 2 years old), addresses the 

weaker protection preventing pertussis after primary vaccination.

 We are developing a potential China best-in-class DTcP vaccine

 for infants. As compared with the co-purified DTaP vaccines, 

 ourDTcP Infant candidate demonstrates fewer sideeffects and

 conveys better and more consistent immunogenicity.

 As compared with Pentaxim, which is the only vaccine in

 China with a DTcP component, our DTcP Infant candidate demonstrated better immunogenicity in pre-clinical studies. Our DTcP Infant candidate received CTA approval in 2018. We have commenced a phase I clinical trial, which we expect to complete in 2019.